Not a statin. Still a question.
PCSK9 inhibitors don't block the mevalonate pathway. That's a genuine advantage over statins. But they drive LDL to levels the human body has never routinely operated at — and the largest trial found no mortality benefit. Different mechanism. Same foundational question: is cholesterol the enemy, or is it a molecule your body makes for a reason?
What this page is not
This is not the statins page. PCSK9 inhibitors don't suppress CoQ10, vitamin K2, steroid hormone synthesis, dolichols, or prenylation. The mevalonate pathway concerns documented there do not apply here. What applies here is a different set of questions — about what happens when you aggressively clear a molecule that every cell in your body uses.
How PCSK9 inhibitors work.
They don't block cholesterol production. They accelerate its removal.
PCSK9 tags LDL receptors for destruction. Your liver clears LDL from the blood using LDL receptors on its surface. PCSK9 binds to these receptors and marks them for degradation. Fewer receptors = less clearance = higher LDL.
The drug blocks PCSK9. Monoclonal antibodies (Repatha, Praluent) bind PCSK9 in the blood before it can reach LDL receptors. More receptors survive. The liver pulls more LDL out of circulation.
LDL drops dramatically. On top of a statin, PCSK9 inhibitors cut LDL by another 50–60%. The FOURIER trial achieved a median LDL of 30 mg/dL. Some patients reached the teens.
What they don't do
- • Don't block HMG-CoA reductase
- • Don't suppress CoQ10
- • Don't reduce K2 (MK-4) synthesis
- • Don't impair prenylation or dolichols
- • Don't directly cause insulin resistance
What they do
- • Drive LDL to historically unprecedented levels
- • Reduce delivery of cholesterol to peripheral tissues
- • Reduce substrate for hormones and vitamin D
- • Stack on top of statins in nearly all cases
- • Cost ~$5,800/year per patient
Patients in FOURIER — the largest PCSK9 inhibitor outcomes trial
Median LDL (mg/dL) achieved — some patients reached below 20
Reduction in cardiovascular death or all-cause mortality in FOURIER
28,000 patients. LDL at 30. No one lived longer.
If “lower is better” were the whole story, FOURIER should have been a triumph. Instead, it found nonfatal event reductions but zero mortality benefit.
The question this raises
If LDL is truly the causal agent of cardiovascular disease — if the relationship is linear and “lower is better” — then a 70% additional reduction in a high-risk population should produce a dramatic mortality signal. The absence of one, in 28,000 patients over 2.2 years, is not easily explained by the LDL hypothesis alone.
They're almost always stacked on statins.
In practice, PCSK9 inhibitors are prescribed on top of maximally tolerated statin therapy. The patient gets both mechanisms simultaneously.
From the statin
Mevalonate pathway suppression: CoQ10 depletion, K2 suppression, reduced prenylation, impaired hormone substrate, calcification risk.
From the PCSK9 inhibitor
Aggressive LDL clearance: whatever cholesterol the statin didn't prevent from being made gets pulled out of circulation before tissues can use it.
Less made + more removed = ?
The statin reduces cholesterol production. The PCSK9 inhibitor accelerates cholesterol clearance. The patient gets both. No major trial has studied whether this combination worsens K2 status, accelerates calcification, or depletes hormones more than a statin alone. The question has not been asked.
The brain at very low LDL.
19 months is not enough
The EBBINGHAUS cognitive substudy followed ~1,974 patients for 19 months and found no significant decline. This is routinely cited as safety clearance. But these drugs are intended for decades of use, and neurodegenerative processes unfold over years. A 19-month all-clear for a 30-year drug is not reassuring.
The U-shaped curve persists
The UK Biobank data on 147,000+ people showing both very high and very low LDL associated with worse cognitive performance doesn't distinguish by mechanism. It suggests the level may matter, regardless of how you got there.
The hemorrhagic stroke signal
Meta-analyses have found associations between very low LDL and increased hemorrhagic stroke risk. The brain's vascular integrity depends in part on membrane cholesterol content. Driving LDL below 30 mg/dL pushes into territory where this signal has not been adequately studied.
Follow the money.
The enthusiasm for PCSK9 inhibitors exists in a financial context that should be named.
Generic atorvastatin per year
Repatha per year
The prescription context
When a cardiologist pushes Repatha, that recommendation occurs alongside pharmaceutical rep visits, speaker programs, advisory boards, and direct-to-consumer advertising. None of this means the drug is ineffective. It means the enthusiasm should be evaluated alongside the financial ecosystem that generates it.
The expansion play
Inclisiran (Leqvio) — an siRNA that silences PCSK9 production — requires only two injections per year at ~$6,500/year. Novartis is positioning it for even broader use. The mortality outcomes trial (ORION-4) is still ongoing. The drug is being marketed before the survival question has been answered.
“But people with natural low PCSK9 are fine.”
People born with PCSK9 loss-of-function mutations have lifelong low LDL and appear to have lower cardiovascular risk. This is cited as proof the drugs are safe. The analogy breaks down in several ways.
Lifetime adaptation ≠ pharmacological crash
A body that develops from conception with low LDL adapts at every level. Taking a 60-year-old and dropping their LDL by 70% is not the same biological event.
Survivorship bias
We study people who survived to adulthood with these mutations. The full developmental and reproductive consequences across a large population are unknown.
Compensatory mechanisms
People with lifelong low LDL may upregulate alternative cholesterol delivery pathways over decades. A drug that rapidly depletes LDL doesn't give the body time to adapt.
Citing natural variants as proof of drug safety is like arguing that because some people thrive on 4 hours of sleep, pharmacologically suppressing sleep to 4 hours would be safe. Genetic adaptation is not pharmacological intervention.
Different drug. Same question.
PCSK9 inhibitors don't shut down the mevalonate pathway. That matters. But they share the foundational assumption that LDL is the enemy and lower is always better. The FOURIER trial tested this aggressively and found no mortality benefit. The cost is $5,800/year. The long-term cognitive data doesn't exist. And they're stacked on top of statins whose downstream effects remain unaddressed.
The right questions about PCSK9 inhibitors are not the same as the right questions about statins. But they lead to the same place: what is cholesterol actually for, and what happens when we declare war on it?